玻璃体内注射贝伐单抗治疗外伤性脉络膜新生血管膜
Intravitreal bevacizumab in the management of posttraumatic choroidal neovascular membrane.
作者信息
Rishi Pukhraj, Shroff Daraius, Rishi Ekta
机构信息
From Sankara Nethralaya, Chennai, India.
出版信息
Retin Cases Brief Rep. 2008 Summer;2(3):236-8. doi: 10.1097/ICB.0b013e31815e9419.
PURPOSE
To report the therapeutic response in the treatment of juxtafoveal choroidal neovascular membrane (CNVM) secondary to traumatic choroidal rupture with intravitreal bevacizumab.
METHODS
A 20-year-old man presented with distortion of central vision following blunt trauma and was found to have juxtafoveal, classic CNVM associated with a choroidal rupture. The patient underwent intravitreal bevacizumab (1.25 mg/0.05 mL) and was periodically followed up.
RESULTS
Four weeks post injection, best-corrected visual acuity improved to 20/20. Optical coherence tomography revealed regression of CNVM and resolution of subretinal fluid. The anatomic and functional status of the treated eye was maintained at 6 months follow-up. No treatment-related ocular or systemic adverse effects were noted.
CONCLUSION
Bevacizumab appears to be safe and effective in the treatment of CNVM secondary to choroidal rupture.
目的
报告玻璃体内注射贝伐单抗治疗外伤性脉络膜破裂继发的黄斑旁脉络膜新生血管膜（CNVM）的治疗反应。
方法
一名20岁男性在钝挫伤后出现中心视力扭曲，被发现有黄斑旁典型CNVM并伴有脉络膜破裂。该患者接受了玻璃体内注射贝伐单抗（1.25毫克/0.05毫升）并定期随访。
结果
注射后四周，最佳矫正视力提高到20/20。光学相干断层扫描显示CNVM消退，视网膜下液吸收。在6个月的随访中，患眼的解剖和功能状态得以维持。未观察到与治疗相关的眼部或全身不良反应。
结论
贝伐单抗在治疗脉络膜破裂继发的CNVM方面似乎安全有效。
Zotero 插件